Saturday, January 07, 2017 3:36:26 PM
Initiation of Phase II dose optimization study in high & very high risk MDS (1H 2017).
"Agree to share cost of Phase II study to explore optimal dosing regimen of Pracinostat + azacitidine in high and very high risk MDS".
Anyway, royalties will depend on revenues and if 401 will show great data results on Q1, we can see some interest from BP as well.
Recent MEIP News
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
- MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 • Business Wire • 01/16/2024 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 10:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:26:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 02:25:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:00:09 PM
- MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 • Business Wire • 12/11/2023 05:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 01:59:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:06:11 PM
- MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/08/2023 10:03:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/08/2023 10:02:50 PM
- MEI Pharma to Present at the Stifel 2023 Healthcare Conference • Business Wire • 11/08/2023 01:00:00 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM